Drug profile · INN
ceritinib
ZYKADIA
ceritinib (ZYKADIA) is a eml4-alk. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — ceritinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
ceritinib (ZYKADIA) is a eml4-alk. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
EML4-ALK
Primary target: ALK tyrosine kinase receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ceritinib?
ceritinib (ZYKADIA) is a eml4-alk. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ceritinib?
ZYKADIA is a marketed brand name for ceritinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ceritinib?
ceritinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.